FDA
approval
· 2023-06-20
FDA Approved: SYNJARDY XR — Supplemental Application (Boehringer Ingelheim Pharmaceuticals, Inc.)
Summary
The FDA approved a supplemental application for SYNJARDY XR (empagliflozin/metformin hydrochloride) by Boehringer Ingelheim Pharmaceuticals, Inc.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
SUPPL AP for SYNJARDY XR (EMPAGLIFLOZIN, METFORMIN HYDROCHLORIDE)